|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0007082,
umls-concept:C0021968,
umls-concept:C0027651,
umls-concept:C0030705,
umls-concept:C0031327,
umls-concept:C0229671,
umls-concept:C0521362,
umls-concept:C0920321,
umls-concept:C1337615,
umls-concept:C1513446
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1996-7-30
|
|
pubmed:abstractText |
COL-1 is a high-affinity murine monoclonal antibody (MAb) specific for carcinoembryonic antigen (CEA). A phase I trial was conducted in which a uniform quantity of antibody labeled with escalating doses of iodine 131 (131I) was administered to patients with advanced gastrointestinal (GI) malignancies to evaluate tolerance and pharmacokinetics.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AllegreGG,
pubmed-author:CarrasquilloJJ,
pubmed-author:ChungYY,
pubmed-author:CuryJJ,
pubmed-author:EggenspergerDD,
pubmed-author:FeueresteinII,
pubmed-author:GrenMM,
pubmed-author:MilenicDD,
pubmed-author:PainFF,
pubmed-author:PerentesisPP,
pubmed-author:PuC QCQ,
pubmed-author:ReynoldsJJ,
pubmed-author:SchlomJJ,
pubmed-author:SilerKK,
pubmed-author:YuBB
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1798-809
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8656248-Antibodies, Monoclonal,
pubmed-meshheading:8656248-Carcinoembryonic Antigen,
pubmed-meshheading:8656248-Colorectal Neoplasms,
pubmed-meshheading:8656248-Dose-Response Relationship, Radiation,
pubmed-meshheading:8656248-Gastrointestinal Neoplasms,
pubmed-meshheading:8656248-Humans,
pubmed-meshheading:8656248-Iodine Radioisotopes,
pubmed-meshheading:8656248-Pancreatic Neoplasms,
pubmed-meshheading:8656248-Radioimmunotherapy,
pubmed-meshheading:8656248-Radiotherapy Dosage,
pubmed-meshheading:8656248-Stomach Neoplasms
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.
|
|
pubmed:affiliation |
Navy Medical Oncology Branch, National Cancer Institute National Institutes of Health, Bethesda, MD USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
